{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:45:57Z","timestamp":1778291157211,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.eururo.2022.07.018","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T06:43:03Z","timestamp":1662705783000},"page":"212-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial"],"prefix":"10.1016","volume":"83","author":[{"given":"Martin","family":"B\u00f6gemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teuvo L.J.","family":"Tammela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albertas","family":"Ulys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egils","family":"Vjaters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Polyakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindaugas","family":"Jievaltas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murilo","family":"Luz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Alekseev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Lebret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schostak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Aude","family":"Le Berre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ateesha F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Sarapohja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.07.018_b0005","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41391-020-00310-3","article-title":"Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors","volume":"24","author":"Saad","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.07.018_b0010","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920978134","article-title":"Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer","volume":"12","author":"Lavaud","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40271-017-0227-y","article-title":"Symptoms and impacts in non-metastatic castration-resistant prostate cancer: qualitative study findings","volume":"10","author":"Tomaszewski","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.eururo.2022.07.018_b0020","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0025","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1002\/cncr.25762","article-title":"Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer","volume":"117","author":"Smith","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.07.018_b0030","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.07.018_b0035","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.07.018_b0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2020.08.025","article-title":"Prostate-specific antigen progression in enzalutamide-treated men with nonmetastatic castration-resistant prostate cancer: any rise in prostate-specific antigen may require closer monitoring","volume":"78","author":"Saad","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.07.018_b0045","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0050","first-page":"e238","article-title":"Prognostic factors for prostate cancer endpoints following biochemical failure: a review of the literature","volume":"7","author":"Nguyen","year":"2015","journal-title":"Cureus"},{"key":"10.1016\/j.eururo.2022.07.018_b0055","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1002\/1097-0142(19931101)72:9<2638::AID-CNCR2820720919>3.0.CO;2-N","article-title":"Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer","volume":"72","author":"D'Amico","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2022.07.018_b0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1464-410X.2010.09878.x","article-title":"Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database","volume":"108","author":"Antonarakis","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.07.018_b0065","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.clgc.2019.08.002","article-title":"PSA doubling time and absolute PSA predict metastasis-free survival in men with biochemically recurrent prostate cancer after radical prostatectomy","volume":"17","author":"Markowski","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2022.07.018_b0070","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/14737140.2021.1856661","article-title":"To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?","volume":"21","author":"Caffo","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.eururo.2022.07.018_b0075","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.euo.2021.04.011","article-title":"Integrating prostate-specific antigen kinetics into contemporary predictive nomograms of salvage radiotherapy after radical prostatectomy","volume":"5","author":"Campbell","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0080","unstructured":"National Institute for Health and Care Excellence. Enzalutamide for hormone-relapsed non-metastatic prostate cancer. Technology appraisal guidance TA580. www.nice.org.uk\/guidance\/ta580."},{"key":"10.1016\/j.eururo.2022.07.018_b0085","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento Terap\u00e9utico de darolutamida (Nubeqa\u00ae) en c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n no metast\u00e1sico. https:\/\/www.aemps.gob.es\/informa\/informes-de-posicionamiento-terapeutico\/informe-de-posicionamiento-terapeutico-de-darolutamida-nubeqa-en-cancer-de-prostata-resistente-a-la-castracion-no-metastasico\/."},{"key":"10.1016\/j.eururo.2022.07.018_b0090","doi-asserted-by":"crossref","unstructured":"Mottet N, Cornford P, van den Bergh RCN, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer 2021. https:\/\/uroweb.org\/guideline\/prostate-cancer\/.","DOI":"10.1016\/j.eururo.2020.09.046"},{"key":"10.1016\/j.eururo.2022.07.018_b0095","author":"Lowrance"},{"key":"10.1016\/j.eururo.2022.07.018_b0100","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.eururo.2018.07.035","article-title":"Managing nonmetastatic castration-resistant prostate cancer","volume":"75","author":"Mateo","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.07.018_b0105","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.07.018_b0110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.clgc.2018.07.017","article-title":"Clinical development of darolutamide: a novel androgen receptor antagonist for the treatment of prostate cancer","volume":"16","author":"Fizazi","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2022.07.018_b0115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2021.06.010","article-title":"Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial","volume":"154","author":"Smith","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2022.07.018_b0120","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2022.07.018_b0125","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.07.018_b0130","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1200\/JCO.2019.37.7_suppl.156","article-title":"Higher blood\u2013brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography","volume":"37","author":"Zurth","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0135","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1200\/JCO.2020.38.6_suppl.326","article-title":"Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers","volume":"38","author":"Williams","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0145","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: in vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.eururo.2022.07.018_b0150","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.canep.2015.05.008","article-title":"Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy","volume":"39","author":"Nguyen-Nielsen","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.eururo.2022.07.018_b0155","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/pcan.2015.25","article-title":"Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Moreira","year":"2015","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.07.018_b0160","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.urology.2016.06.011","article-title":"Predictors of time to metastasis in castration-resistant prostate cancer","volume":"96","author":"Moreira","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2022.07.018_b0165","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0170","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1111\/bju.13856","article-title":"Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer","volume":"120","author":"Howard","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2022.07.018_b0175","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.euf.2018.03.010","article-title":"Time-to-event outcomes in men with nonmetastatic castrate-resistant prostate cancer\u2014a systematic literature review and pooling of individual participant data","volume":"5","author":"Aly","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2022.07.018_b0180","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41391-018-0095-0","article-title":"Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer","volume":"22","author":"Whitney","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2022.07.018_b0185","doi-asserted-by":"crossref","first-page":"930.e13","DOI":"10.1016\/j.urolonc.2020.07.002","article-title":"Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer","volume":"38","author":"Freedland","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2022.07.018_b0190","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.07.018_b0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2022.07.018_b0200","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2019.37.7_suppl.185","article-title":"A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: post-hoc analysis of PROSPER by prior therapy","volume":"37","author":"De Giorgi","year":"2019","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.eururo.2022.11.018","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000}}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822025325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822025325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T01:11:08Z","timestamp":1708477868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822025325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0302283822025325"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.07.018","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}